photo #8681203

🚨BREAKING STUDY: Intranasal Nano-Ivermectin Shrinks Brain Tumors by 70% Without ToxicityLandmark preclinical study shows intranasal ivermectin nanocapsules safely shrink glioblastoma in animal models at doses lower than the approved human antiparasitic dose 👇📍Rats with implanted glioblastoma tumors received intranasal nano-ivermectin for 10 days at 60 µg/day — a dose below the approved human antiparasitic level.📉Tumor volume dropped by ≈70% compared to untreated controls (79 mm³ vs 254–277 mm³).📉The treatment also reduced necrosis, edema, and vascular proliferation, indicating less invasive and aggressive tumors.✅No toxicity was observed — normal liver, kidney, blood, and lung histology; body weight unchanged throughout treatment.Other formulations — free ivermectin and silica-based particles — showed no significant tumor reduction, highlighting key role of nanocapsule delivery for brain targeting.These findings align with ivermectin’s 14 distinct anti-cancer mechanisms summarized by Yuwen et al, encompassing inhibition of oncogenic signaling (YAP1, Wnt–TCF, Akt/mTOR, EGFR/NF-κB, MAPK), mitochondrial and oxidative-stress induction, ion-channel modulation, and suppression of both cancer stem cells and the epithelial–mesenchymal transition (EMT).Clinical translation in humans is urgently needed.